| Date Filed | Type | Description |
| 08/17/2023 |
SC 13D/A
| BIOTECHNOLOGY VALUE FUND L P reports a 20.8% stake in Pieris Pharmaceuticals, Inc. |
| 08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/18/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/08/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/30/2023 |
4
| KIRITSY CHRISTOPHER P (Director) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.|
Txns:
| Bought 10,000 shares
@ $0.85, valued at
$8.5k
|
|
| 05/19/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended March 31, 2023 2022 Revenues $ 1,936 $ 10,988 Operating expenses Research and development 13,424 14,066 General and administrative 4,023 4,379 Total operating expenses 17,447 18,445 Loss from operations Interest income 357 Grant income 2,028 2,130 Other income , net (57 229 Net loss",
"Investor Presentation, dated May 2023" |
|
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
4
| Bures Thomas (CFO) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.|
Txns:
| Granted 249,080 options to buy
@ $1.39, valued at
$346.2k
|
|
| 02/28/2023 |
4
| Kaufmann Hitto (Chief Scientific Officer) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.|
Txns:
| Granted 249,080 options to buy
@ $1.39, valued at
$346.2k
|
|
| 02/28/2023 |
4
| Mousa Ahmed (Chief Business Officer) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.|
Txns:
| Granted 249,080 options to buy
@ $1.39, valued at
$346.2k
|
|
| 02/28/2023 |
4
| Yoder Stephen S. (CEO) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.|
Txns:
| Granted 634,021 options to buy
@ $1.39, valued at
$881.3k
|
|
| 02/14/2023 |
SC 13G/A
| Lynx1 Capital Management LP reports a 7.6% stake in Pieris Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Aquilo Capital Management, LLC reports a 7.5% stake in PIERIS PHARMACEUTICALS, INC. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| ASTRAZENECA PLC reports a 4.8% stake in PIERIS PHARMACEUTICALS, INC. |
| 01/27/2023 |
SC 13G
| Soleus Capital Master Fund, L.P. reports a 5.4% stake in PIERIS PHARMACEUTICALS, INC. |
| 01/26/2023 |
SC 13G/A
| Soleus Capital Master Fund, L.P. reports a 1.3% stake in PIERIS PHARMACEUTICALS, INC. |
| 01/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/16/2022 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 11/04/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/04/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
8-K
| Quarterly results |
| 11/01/2022 |
8-K
| Quarterly results |
| 10/24/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/13/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/04/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|